The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

PHASE4RecruitingINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2026

Conditions
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Interventions
DRUG

Silodosin Capsules

Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.

DRUG

Ningmitai capsule

Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

DRUG

Tamsulosin

Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

Trial Locations (8)

Unknown

NOT_YET_RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

RECRUITING

Beijing Tongren Hospital, Capital Medical University, Beijing

NOT_YET_RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

NOT_YET_RECRUITING

Peking University Shenzhen Hospital, Shenzhen

NOT_YET_RECRUITING

The Central Hospital Of WUHAN, Wuhan

NOT_YET_RECRUITING

Wuhan No.1 Hospital, Wuhan

NOT_YET_RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

NOT_YET_RECRUITING

Wuxi No.2 People's Hospital, Wuxi

All Listed Sponsors
lead

Xintian Pharmaceutical

INDUSTRY